Published online Apr 28, 2024. doi: 10.3748/wjg.v30.i16.2285
Peer-review started: January 16, 2024
First decision: February 26, 2024
Revised: March 7, 2024
Accepted: April 2, 2024
Article in press: April 2, 2024
Published online: April 28, 2024
Processing time: 101 Days and 2 Hours
This is a retrospective study focused on recompensation after transjugular intrahepatic portosystemic shunt (TIPS) procedure. The authors confirmed TIPS could be a treatment for recompensation of patients with cirrhosis according to Baveno VII. The paper identified age and post-TIPS portal pressure gradient as independent predictors of recompensation in patients with decompensated cirrhosis after TIPS. These results need to be validated in a larger prospective cohort.
Core Tip: Approximately one-third of the patients experienced cirrhosis recompensation following transjugular intrahepatic portosystemic shunt (TIPS) and post-TIPS portal pressure gradient reduction below 12 mmHg contributes to the occurrence of recompensation. The selection of a smaller diameter (6 mm) stent may be an effective measure to reduce portal vein pressure while decreasing the incidence of postoperative hepatic encephalopathy.
- Citation: Jin YN, Zhang W. Transjugular intrahepatic portosystemic shunt: A promising therapy for recompensation in cirrhotic patients. World J Gastroenterol 2024; 30(16): 2285-2286
- URL: https://www.wjgnet.com/1007-9327/full/v30/i16/2285.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i16.2285
Cirrhosis recompensation, as defined by the Baveno VII consensus, refers to a condition in which patients with decompensated cirrhosis exhibit stable improvement in liver function without any episodes of decompensation over an extended period, following effective etiological therapy[1]. Effective etiological treatment is paramount for re-compensation and involves sustained alcohol abstinence in cases of alcohol-induced cirrhosis, sustained viral suppression in hepatitis B-related cirrhosis, and viral elimination in hepatitis C-related cirrhosis. However, research on the recompensation of cirrhosis due to other causes remains scarce.
The transjugular intrahepatic portosystemic shunt (TIPS) procedure reduces the portal pressure gradient (PPG) and is primarily utilized to manage various complications of portal hypertension in cirrhotic patients, such as esophagogastric variceal bleeding and refractory ascites. Thus, TIPS may promote recompensation in patients with decompensated cirrhosis. The study by Gao et al[2] was pioneering in investigating the impact of TIPS on recompensation across different etiologies of decompensated cirrhosis. Their findings indicated that approximately one-third of the patients achieved cirrhosis recompensation following TIPS and identified a postoperative PPG of less than 12 mmHg as an independent predictor of cirrhosis recompensation. Although a reduction in PPG is associated with a decreased risk of variceal rebleeding, the risk of hepatic encephalopathy post-TIPS escalates with the magnitude of PPG reduction[3], potentially impeding recompensation. Consequently, employing small-diameter (6-mm) stents may be an effective strategy to mitigate portal hypertension and minimize the risk of postoperative hepatic encephalopathy, warranting further investigation. Additionally, the findings of this study necessitate validation in a larger, prospective cohort due to its limited sample size and retrospective nature. Furthermore, including only TIPS patients limits the study; comparing the recompensation frequency between TIPS and non-TIPS groups could elucidate the procedure's facilitative role in cirrhosis recompensation. Future research should elucidate how TIPS influences recompensation across various cirrhosis etiologies, with a focus on developing tailored treatment strategies to enhance patient outcomes.
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Gastroenterology and hepatology
Country/Territory of origin: China
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Giri S, India S-Editor: Qu XL L-Editor: A P-Editor: Chen YX
1. | de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76:959-974. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 952] [Cited by in F6Publishing: 1110] [Article Influence: 555.0] [Reference Citation Analysis (1)] |
2. | Gao L, Li MB, Li JY, Liu Y, Ren C, Feng DP. Impressive recompensation in transjugular intrahepatic portosystemic shunt-treated individuals with complications of decompensated cirrhosis based on Baveno VII criteria. World J Gastroenterol. 2023;29:5383-5394. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (2)] |
3. | Liao Y, Zhang L, Wang JT, Yue ZD, Fan ZH, Wu YF, Zhang Y, Dong CB, Wang XQ, Cui T, Meng MM, Bao L, Chen SB, Liu FQ, Wang L. A novel nomogram predicting overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in portal hypertension patients. Sci Rep. 2023;13:15244. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |